Drug Profile
NNC 01940499
Alternative Names: NN 9500; NN9499; NNC-0194-0499Latest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Hepatoprotectants; Obesity therapies
- Mechanism of Action Fibroblast growth factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Phase I Non-alcoholic fatty liver disease
- No development reported Obesity
Most Recent Events
- 09 Feb 2024 Novo Nordisk completes a phase I trial in Non-alcoholic steatohepatitis (Monotherapy, In volunteers) and Non-alcoholic steatohepatitis (Combination therapy, In volunteers) in Canada (SC) (NCT05766709)
- 18 Dec 2023 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in Austria (SC) (NCT06188026)
- 10 Nov 2023 Novo Nordisk completes a phase I trials in Non-alcoholic steatohepatitis (In adults, In the elderly) in Germany (SC) (NCT05727644) (EudraCT2022-001849-20)